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Comparison of hock- and footpad-injection
as a prostate adenocarcinoma model in
rats
Henning Richter1,2* , Agnieszka Karol2, Katja Nuss2, Aymone Lenisa2, Erika Bruellmann4, Stella-Saphira Maudens5,
Heinrich Hoffmann5, Brigitte von Rechenberg2,3 and Patrick R. Kircher1,3
Abstract
Background: Objective of this study is a feasibility-test comparing hock- and footpad-injection in rats with inoculated
MatLyLu - adenocarcinoma tumor model. This study compares the development of an adenocarcinoma model
(MatLyLu) in 12 Copenhagen rats. Two groups (n = 6) of animals were inoculated with 1 × 106 MatLyLu tumor cells
solved in 0.1 ml NaCl either by footpad or hock injection. All animals were examined before tumor inoculation and
before euthanasia using a 3.0 Tesla MRI. Histological evaluation of all organs was performed post mortem.
Results: Both types of injection were able to induce the adenocarcinoma model using MatLyLu tumor cells. The
primary tumor could be visualized in MRI and confirmed histologically. Comparing the risk of reflux and the maximum
injection volume during injection, the hock injection was superior to the footpad injection (less reflux, less anatomical
restrictions for larger volumes). The hock injection induces a faster tumor growth compared to the footpad injection.
As consequence the maximum level of long term discomfort after hock injection was reached earlier, even if it grew
on a not weight bearing structure. Early lymph node tumor metastasis could not be observed macroscopically nor
detected histologically. Therefore the reproducibility of the MatLyLu tumor model is questionable.
Conclusion: Hock injection is a feasible alternative technique compared with footpad-injection in rats. It provides a
save and easy injection method for various early-terminated applications with the potential to increase animal welfare
during tumor models in rats.
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Background
Prostate cancer in human varies in differentiation and
pathology, as well as in responsiveness to treatment.
Prostate cancer is a common cancer in men in Europe
with the incidence of clinically diagnosed patients in
northern and western Europe > 200 per 100,000 men/
year. [1] Beside some rare types of neuroendocrine pros-
tate cancers (small or large cell prostate cancer), the
most common type is the adenocarcinoma, with its ori-
gin at the glandular epithelial. In the following, the term
prostate cancer is used for the adenocarcinoma type.
Diagnostic methods are based on PSA (Prostate Specific
Antigen) screening and digital rectal examination (DRE)
with subsequent transrectal ultrasound guided (TRUS)--
guided biopsy. Prostate cancer is suspected on the basis
of these examinations, but the definitive diagnosis de-
pends on histopathological verification. [1]
Localized or locally advanced prostate cancer has 3
major treatment options: observation, surgery and radi-
ation. There are other nonstandard treatment options,
which include cryotherapy, high-intensity focused ultra-
sound, and primary hormone therapy. Choosing the best
treatment is generally based on the patient’s age, the
stage and grade of the cancer, the general health, and
evaluation of the risks and benefits of each therapy
option.
A strong need exists for a reliable animal model of
prostate cancer that reflects different tumor stages and
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can be translated into human patients to study several
therapeutic approaches. An animal model needs to be
based on proper experimental design and should in-
crease the understanding of the biology of this disease.
From all established rodent models of prostate cancer
the Dunning model is well described and characterized
by rapid growth of primary tumor and production of
metastases. [2] The Dunning model has been obtained
from Dunning prostate tumor-bearing Copenhagen rats
on the strongly metastatic MAT-LyLu cell line. The lat-
ter can be transplanted and transfected. Histologically
the tumor is characterized as an undifferentiated ana-
plastic form, proves invasive and fast growing as well as
spreading into surrounding tissue. [3] There are different
methods described for developing a locally advanced
orthotopic primary tumor based on percutaneous injec-
tion of the cells in the area of interest. [4] Footpad injec-
tion is a commonly used immunization method in mice,
alternatively the hock injection has been utilized as less
painful considering the weight-bearing structures. [5] To
the best of the authors knowledge hock injection has
never been tested in rats for induction of tumors before.
Considering the animal size, hock injection in rats could
be beneficial for the general macroscopical and radio-
logical screening. It would also facilitate the amount of
tissue obtained for processing. Metastatic involvement of
the injection-site associated tumor can be estimated
through examination of lymphatic components. Under-
taken the pattern of lymphatic drainage in adult labora-
tory rats [6] the metastatic activity is expected to be
primarily in popliteal and inguinal lymph nodes in case
of proximal metastases and secondarily in pulmonary
lymph nodes and other organs. Histological and radio-
logical nodal staging with detecting possible metastases
is a routine method in medical diagnostics.
The aim of this study was to evaluate the feasibility of
two inoculation methods (footpad versus hock injection)
of an adenocarcinoma cells (MatLyLu) in Copenhagen
rats and to evaluate both using a specially developed
score sheet for animal health (Additional file 1). The
examination included tumor behavior, tumor biology
and metastatic potential using an appropriate image
guidance (MRI) and histological characterization. Fur-
thermore we aimed to compare these two methods con-
sidering the general animal welfare. The hypothesis was,
that the hock injection is an alternative method for use
in tumor models in rats.
Results
All animals could be treated as planned and were included
in the results. During anesthesia no complications were
observed. The usage of anesthesia antagonists resulted in
a fast and smooth recovery from anesthesia.
A small amount of reflux was observed twice after
footpad injection. However, the primary tumor could be
induced in all cases over time. Differences were noticed
regarding their speed of development with earlier signs
in the hock injection group.
In the first 5 days after inoculation tumor development
could not be observed, neither for footpad nor for the
hock injection technique. Thereafter, onset of tumor de-
velopment could be clinically observed in the hock injec-
tion group at 7 days after tumor inoculation compared
with 10 days after footpad injection. The spread of the
tumor was limited to the surrounding soft tissue for
both groups. The fast growing tumor in the hock injec-
tion group was palpable under the skin and was located
at the injection site. At eight days after tumor inocula-
tion at the hock, all animals developed a distinct primary
tumor. In the footpad group, a distinct primary tumor
developed 11 days after injection, which was like in the
hock injection group located and limited to the injection
site (swollen foot). (Figure 1).
The maximum survival time was reached after 18 days
in the hock injection group and after 21 days in the foot-
pad injection group. In both cases animals were unable
to put weight on their injected limbs.
The imaging protocol proved suitable in all cases and
confirmed growth of the primary tumor while it also en-
abled monitoring of popliteal lymph nodes prior to
organ sampling. Fat suppression techniques allowed
visualizing lymph nodes without surrounding fat and
documenting their size.
All primary tumors identified by MRI where con-
firmed macroscopically during organ sampling and later
also histopathologically. Based on MRI images, the size
of both popliteal lymph nodes was measured in width
and length before tumor inoculation (first MR) and dir-
ectly before euthanasia (second MR). The measured size
of the popliteal lymph nodes on the tumor-bearing limb
(right side) differed significantly between the first and
the second MRI (width right: p = 0.000, length right: p =
0.008). Splitting the data by type of injection showed sig-
nificance between MRI examinations on the right side
after hock injection (width right: p = 0.009, length right:
p = 0.041). All results are summarized in Table 1.
Macroscopically the primary tumors after hock injec-
tion were larger in size. They strongly compressed adja-
cent tissue and exhibited more necrosis and also
hemorrhage compared to the primary tumor after foot-
pad injection.
Histopathologically the primary tumors could be iden-
tified as a high-grade malignant adenocarcinoma inde-
pendent of injection site, with the same morphology
score (meanFP: 2.50 ± 0.71, meanHock: 2.50 ± 0.71). The
samples of the primary tumors showed all typical signs
of malignancy (mitoses, cellular atypia, cellular apoptosis,
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presence of vascular invasion, hemorrhage, necrosis, com-
pression of adjacent tissue). (Figure 2).
All other organs were structurally unremarkable (HE).
Metastases in distant organs (lungs, liver, spleen, kidneys,
adrenals, muscle) could not be detected, neither during
MRI examination nor later during screening the histo-
logical sections (HE). Scoring of structural changes in pop-
liteal lymph nodes (HE) reached slightly higher scores in
the tumor bearing right leg (meanFP: 1.25 ± 0.83, meanHock:
0.50 ± 0.50) compared with the left control side (meanFP:
1.00 ± 0.71, meanHock: 0.25 ± 0.43). Additional IHC (Lu-5,
Galectin 3, PSA) was negative for tumor cells and showed
unspecific reaction with staining of normal structures: mac-
rophages, plasma cells and some tissue background.
Although lymph nodes showed a middle to severe a react-
ive tissue structure, early lymph node tumor metastasis
could not be observed macroscopically nor detected histo-
logically (no tumor nests or single tumor cells).
Fig. 1 a-d) photographs of footpad injection (FP) - primary tumor (right) in comparison with control side (left); a): footpad injection; b): primary
tumor after FP (21 days); c): primary tumor after FP (21 days); d) control side after NaCl FP (21 days). e-h) photographs of Hock injection (Hock) -
primary tumor (right) in comparison with control side (left); e): Hock injection; f): primary tumor after Hock injection (18 days); g) control side after
NaCl Hock injection (18 days); h): primary tumor after Hock injection without fur (18 days)
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Discussion
For animal studies in rodents, tumor induction is a
widely used technique to observe tumor biology [7],
treatment [8] or metastases [9]. Tumor growth and the
behavior of metastases are of primary interest for clinical
diagnosis and treatment planning. This study evaluated
the feasibility of the MatLyLu tumor model by using two
type of injections in Copenhagen rats, the hock or
footpad injection. Although animals of both groups
developed a manifest primary tumor after inoculation,
differences could be detected in time of tumor
development.
Tumor induction differences could be reproduced be-
tween part 1 and part 2 of this study and showed that
the injection type is of importance. Hock injection leads
to a faster growth of the primary tumor, whereas footpad
injection needed 3 days longer until manifestation of the
primary tumor. In addition, hock injection allowed the
primary tumor to develop bigger in size compared to
footpad injection. The very tight structure and limited
amount of surrounding tissue in the animal’s footpad
could explain this. Instead the hock injection offers a lar-
ger subcutaneous space for inoculation with higher vol-
umes and still reduced risk for reflux. Especially studies
with small injection volumes could profit from that ex-
perience, as it is important to avoid reflux in order to
minimize experimental error and variability of the data
observed.
At the same time, the location of injection has a strong
influence on animal welfare. Hock injection was already
applied to study local immune responses in sheep [10–12]
and mice. [5] In these studies it could be observed, that
the level of discomfort was much lower due to tumor
growth on a not-weight bearing area. Any animal model
associated with a fast growing primary tumor may profit
from the use of the hock injection, because thereby no
weight bearing structure is involved. Footpad injection is
always related to a primary lesion on the weight bearing
feet, which results in reduced animal welfare during tumor
development. [5] Systemic limitations after footpad injec-
tion regarding food uptake, activity, mobility or weight
loss were not observed in the initial stage until clinical
Table 1 Descriptive data analysis and Mann-Whitney U-Test between 1st and 2nd MRI, *significant p < 0.05 [Median (Min, Max, p-
value)]
Side Lenght Width
right 3.06 (2.28, 5.73, p = 0.008)* 2.19 (1.58, 3.66, p = 0.000)*
left 2.88 (2.03, 3.28, p = 0.932) 2.02 (1.52, 2.59, p = 0.932)
Type of injection Side Lenght Width
FP right 2.99 (2.29, 5.62, p = 0.132) 2.15 (1.58, 3.22, p = 0.065)
FP left 2.84 (2.45, 3.20, p = 1.000) 1.99 (1.52, 2.30, p = 0.699)
Hock right 3.09 (2.28, 5.73, p = 0.041)* 2.25 (1.68, 3.66, p = 0.009)*
Hock left 2.88 (2.03, 3.28, p = 0.937) 2.09 (1.74, 2.59, p = 0.937)
Fig. 2 a-h) Histological examples of tumor phenotype and immunohistochemical reactions
Richter et al. BMC Veterinary Research          (2018) 14:327 Page 4 of 11
signs of tumor manifestation. However, at a later stage of
tumor growth clinical relevant immobility occurred within
2 days for both types of injections with the first day show-
ing low grade lameness and on the second day non-weight
bearing of the affected limb. This limited the maximum
survival time after hock injection to 18 days compared to
21 days after footpad injection. While on one hand, foot-
pad injection reduces animal welfare during early tumor
development due to tumor growth on the weight bearing
hind leg, it allows prolongation of the maximum survival
time on the other hand. This may be explained by the ana-
tomical related limitations of the tumor growth and size at
the animal’s foot pad.
This difference of tumor size and growth could be ad-
vantageous for specific research questions where time
and size play a role as parameters. In any case this study
showed that both types of injection will be able to reli-
able induces a primary Matlylu primary tumor.
Secondary to the primary tumor, lymph node involve-
ment and metastasis are of interest while studying tumor
models. Lymphatic drainage is already described for
Matlylu. [13] On this account, lymph node involvement
was also observed in the current study during MRI
examination and was verified by histological evaluation.
A significant and remarkable increase of lymph node
size could be detected for popliteal lymph nodes (1st/
2nd MRI size popliteal width right: p = 0.000, 1st/2nd MRI size
popliteal length right: p = 0.008). As they are the sentinel
lymph nodes of the hind limb and both are close to both
injection sites, it was expected to induce lymph node
metastasis of the primary Matlylu tumor. [14–16] Based
on MRI findings the reason for enlargement could not
be differentiated between reactive or metastatic. The im-
aging protocol used in this study was optimized for the
available 3 Tesla MRI. Although this kind of MRI is ori-
ginally not produced for rodents images of a very good
quality were obtained using the settings described above.
The imaging protocol allowed recognizing the primary
tumor as well as normal and enlarged popliteal lymph
nodes. Two ROI were used to optimize settings for in-
creased image quality. One focus was set caudally of the
pelvis to visualize the primary tumor and popliteal re-
gion, the other focus was set for a whole body scan of
the rat to check for metastasis in other organs such as
liver, lungs, brain. Measurements of lymph node size
were based on DICOM images and limited by the small
size of the lymph nodes, which were visible in two to
three slices only.
Histological evaluation of the lymph nodes should help
to clarify the reason for enlargement (reactive or meta-
static). However, neither HE staining nor IHC staining were
able to detect early lymph node metastases (single-cell and
micro-metastases). IHC showed an unspecific reaction and
some tissue background. Based on the fact that primary
tumors between 5th and 21st day were evaluated, we as-
sume that this may be at least partially explained by insuffi-
cient lymph node involvement in early stages. But then, the
lymph nodes of a later stage primary tumor did not show
either any signs of metastatic changes. No differences be-
tween injection types were observed regarding metastatic
lymph node involvement. Based on that finding it could be
concluded that early stage lymph node involvement could
not be detected within reactive changes by using histology.
These findings would go along with earlier studies pub-
lished where it was suggested that the site of tumor inocu-
lation and circulatory anatomy does not influence the
pattern of metastasis development in organs. [17]
As limitations of the study the small number of ani-
mals and asymmetric study design (between part 1 and
part 2) has to be considered. Additionally, neither HE
staining nor IHC staining were able to detect early
lymph node metastases. The conflict between rapid
tumor growth/metastatic activity and animal welfare in-
fluenced the possibility to observe lymph nodes of a later
stage. Since animals after hock injection have a shorter
survival time, researchers using this model will be lim-
ited to a smaller timeframe to study results of interest.
Nevertheless, in both, the animal model with hock and
foot pad injection, Matlylu tumors could be induced and
serve as animal model for further investigations of pros-
tate tumors.
Conclusion
In conclusion hock injection is a feasible alternative
technique compared with footpad-injection in rats. It
provides a save and easy injection method for various
early-terminated applications with the potential to in-
crease animal welfare during tumor models in rats.
Methods
Animals
In the study healthy female Copenhagen rats were used,
which were all research animals. In the first part of the
study 12 animals with a Mean ± SD age of 103 ± 10.8 days
(range 94 to 127 days) and a Mean ± SD body weight of
162 ± 10.6 g (range, 148 to 180 g) and in a second part
of the study 4 animals with a Mean ± SD age of 90.5 ±
4.2 days (range 86 to 95 days) and a Mean ± SD body
weight of 151 ± 8.0 g (range, 144 to 161 g) were used.
After delivery, the animals had seven days of
acclimatization. All animals had free access to food and
water and were placed at a regular light/dark cycle
(7:00 a.m. to 07:00 p.m., light) and a controlled
temperature (20–23 °C). The animals were trained and
accustomed to human handling to reduce stress during
the study. All animals were kept in an open cage system,
group housed (2 animals together) in type T2000 cages
(LxBxH 610x435x215mm). Single housing of animals
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was not necessary, with exception of the last animal of
the cage (for maximum 3 days). During acclimatization
the rats were handled every day to make them familiar
with the research personnel (stress reduction). Once a
day, and after tumor inoculation twice a day, all animals
were checked using a health-check-protocol. The health
check included assessment of mobility, posture, pelt,
eyes, social behavior and weight loss using a specially de-
veloped score sheet for assuring animal well being. In
the first part of the study one animal of each group
(hock vs footpad injection) was observed over a specific
tumor developmental time of 5, 9, 11, 14, 15, 18 and
21 days. In the second part of the study the tumor devel-
opmental time was set at 9, 11, 13 and 15 days depend-
ing on the clinical observations. (Table 2) The tumor
reached its maximum developmental time once the ani-
mal was stopped weight bearing on the injected hind
limb.
Anaesthesia
General anesthesia was necessary for imaging as well as
for a safe and standardized tumor inoculation. The in-
duction of anesthesia was performed by subcutaneous
injection of a drug mixture (1 ml/kg BW), containing
1 ml fentanyl (0.05 mg/ml) with 4 ml midazolam (5 mg/
ml), 1.5 ml medetomidine (1 mg/ml) and 3.5 ml of 0.9%
NaCl. During time of anesthesia the eyes were covered
with ointment (Vitamin A). Anesthesia state was main-
tained by subcutaneous injection of the same drug mix-
ture using 0.5 ml/kg BW every 30–60 min. Anesthesia
was terminated by reversing action of the used
anesthesia drugs. For this purpose a drug mixture was
prepared of 3 ml naloxone (0.4 mg/ml), 20 ml flumazenil
(0.1 mg/ml), 1.5 ml atipamezole (5 mg/ml) and 5.5 ml of
0.9% NaCl and administered intraperitoneally at 3 ml/kg
BW.
Imaging
All MRI examinations were performed with a 3.0 Tesla
scanner with the rats under general anesthesia. During
examination animals were positioned in dorsal recum-
bency with the head towards the gantry. Imaging proto-
cols were adapted over time and used two regions of
interest (ROI). First ROI focused on the hind limbs and
included the primary tumor as well as popliteal lymph
nodes of both sides. The second ROI focused on the
whole body of the rats and included thorax and abdo-
men. The acquired scan protocol contained T1 and T2
Table 2 Table showing study design and allocated groups
Study
part
Animal Type of Injection
[hock = H, FP =
footpad]
Tumor developmental
time
[days]
1 1 H 5
2 FP 5
3 H 9
4 FP 9
5 H 11
6 FP 11
7 H 14
8 FP 14
9 H 15
10 FP 15
11 H 18
12 FP 21
2 13 H 9
14 FP 11
15 H 13
16 FP 15
Fig. 3 MRI Images of Copenhagen rats - pelvic region (left image) and right popliteal lymph node in detail (right image): T2 dorsal; T2 fatsat dorsal; T2
transversal; T2 fatsat transversal; T1 transversal; T1 SPIR transversal
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weighted sequences (Fig. 3). Two different coilsl,m
were used for acquisition of the data (3 T Dual Mi-
croscopy coil 47 mm and M 16c-TR-KneeCoil). Dur-
ing MRI, the rats got earplugs (cotton ball) for noise
and stress reduction. The first MRI examination was
performed directly before tumor cells were inoculated.
The second MRI examination was performed after an
animal dependent tumor development time (5th to
21st day) and followed by euthanasia and organ sam-
pling. After their second MRI all animals were eutha-
nized, while being deeply anesthesized, with 0.5 ml/kg
BW Potassiumchloride intracardially (> 2 mmol/kg
KCl). Based on MRI images the size of lymph nodes
was measured in width and length.
Injections
In this study 1 × 106 MatLyLu tumor cells solved in 0.1 ml
NaCl were injected into 16 Copenhagen rats. Required tests
confirmed that the cells were pathogen free (Additional file
2). They were stored at − 80 °C prior use.
In the first part of the study cells were injected imme-
diately after being thawed. The thawed cell suspension
(1 ml) was transferred into a falcon tube, containing
10 ml NaCl at 37 °C. After centrifuging (150 g for
5 min), the supernatant was removed and resuspended
in 300 μl NaCl. The cells were drawn into the syringe
using a 18 Gauge needle to minimize shear stress.
In the second part of the study, MatLyLu cells were
cultured at 37 °C in a humidified incubator (5% CO2) in
RPMI 1640 medium (containing 2 mM Glutamine), sup-
plemented with 10% fetal bovine serum, 250 nM Dexa-
methasone and 1% penicillin/streptomycin for 7 days
prior to injection. Every second day cells were split 1:20
into a fresh cell culture flask. Prior to in vivo injection,
medium was changed to NaCl and the cell suspension of
1.1 × 106 cells/100 μl was prepared for injection. One
group (8 animals) was injected into the footpad accord-
ing to the “Footpad Injections Guidelines in Mice and
Rats” published by IACUC. [18] The other group (8 ani-
mals) received a hock injection, which was located at the
lateral tarsal region just above the ankle. [5] (Fig. 4) The
Fig. 4 a Foot-pad (FP) and b) Hock Injection - both shown as cartoon and photograph
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tumor cell injections (0.1 ml) were conducted subcuta-
neously with a 25G needle into the right hind limb,
while using the left hind limb as individual control. As
control 0.1 ml 0.9% NaCl was subcutaneously injected.
All injections were done under general anesthesia after
MRI examination. During injection the needle inserted
bevel was turned towards the skin and the mixture was
injected by slow but firm pressure on the syringe plun-
ger. After both injections, a small “bubble” of mixture
was seen subcutaneously at the injection site. At the
a
c
e
g h
f
d
b
Fig. 5 a-e) Series of images during footpad injection technique (FP); f) photograph of Hock injection technique
Table 3 Table showing detailed antibody informations
Marker Provider Order Number Dilution Read-out
Lu5 (Pan-cytokeratin) Abcam ab27988 1:10 Cells of epithelial origin (carcinoma cells)
PSA Abcam ab53774 1:500 Anti-Prostate Specific Antigen
Galactin-3 Abcam ab2785 1:100 Adenoma and carcinoma cells (incl MatLyLu cells (Pienta et al. 1995)
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Table 4 Table showing semiquantitative scoring for histopathology examination
Organ Scoring Description
Liver 0 –
1 mild focal fatty infiltration around central vein(s)
2 mild to moderate fatty infiltration around central
vein(s) and in portal area, sinusoid dilatation
3 severe fatty infiltration around central vein and in portal area, necrosis (hepatocellular dissociation)
Spleen 0 –
1 activated follicles, increased hemosiderosis
2 increase of red and white pulp (follicles etc.),
3 neutrophil granulocytes in red pulp, necrosis, fibrosis
Lymphnodes 0 –
1 secondary follicle activation, cortex vascular lesions (dilation of blood and/or lymphatic vessels)
2 Localized: Secondary follicle activation, follicular depletion (atrophy), lymphatic sinus ectasia,medullar and cortex vascular lesions
(dilation of blood and/or lymphatic vessels), macrophage hyperplasia (cortical-sinus)
3 Whole organ (Cortex, Paracortex, Medulla): Secondary follicle activation, follicular depletion (atrophy), lymphatic sinus ectasia,medullar
and cortex vascular lesions (dilation of blood and/or lymphatic vessels), macrophage hyperplasia (cortical and medullary sinus)
Kidneys 0 –
1 single protein liquid in proximal tubuli
2 generalized protein liquid in proximal tubuli, interstitial nephritis, swollen mesangial cells
3 necrosis, tubulonephrose, atrophic glomeruli, tubular cysts, papillar necrosis, fibrosis
Brain 0 –
1 severe hyperemia and congestion, oedema (widen “Virchof-Robin” space)
2 additional gliosis, single neuron necrosis (shrunken hypereosinophilic neurons)
3 additional severe gliosis/astrocytosis, neuronal necrosis, encephalitis, status spongiosus (severe oedema), lost of myelin sheath
(demyelination)
Lung 0 –
1 severe hyperemia and congestion, alveolar oedema (liquid in alveoli with cellular reaction)
2 additional some inflammatory cells in alveoli/interstiitum (macrophages, lymphocytes, neutrophils)
3 additional multiple inflammatory cells in alveoli/interstiitum (macrophages, lymphocytes, neutrophils), proliferation of bronchial
epithelium, bronchitis
Heart 0 –
1 severe hyperemia and congestion
2 additional single perivascular inflammatory infiltrates and degeneration of myocytes
3 additional myocard necrosis (focal and multifocal), deposits within vascular wall
Adrenal
gland
0 –
1 severe hyperemia and congestion
2 mild cortex/medulla activation (nodular hyperplasia), hypertrophy
3 severe cortex/medulla activation (nodular hyperplasia), hypertrophy
Muscle 0 –
1 severe hyperemia and congestion, interstitial oedema, mild satelitosis
2 additional swelling of the myocytes, degeneration (centraliation of myocytes nuclei), focla loss of striation, hypereosinophilic myocytes
3 additional necrosis, inflammation, fatty infiltration
Tumor 0 –
1 tumor focus in primary organ with local invasion (infiltrative growth)
2 tumor focus in primary organd with invasion and compression of adjacent tissue, mitosis per HPF40x (1–2), metastases in local lymph
node (popliteal LNN)
3 mitosis per HPF40x (3–7), vascular invasion (lymphatics, blood vessels), necrosis, cellular apoptosis, metastases lymph nodes (additional
to popliteal Lnn) and other organs
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time of removing the needle, gentle pressure was applied
to prevent leakage (reflux) (Fig. 5).
Histopathology
Directly after the second MRI examination, the rats were
euthanized and dissected. The following organs were col-
lected and prepared for histopathology: brain, heart, right
middle lung lobe, liver, spleen, kidneys, adrenal glands,
lymph nodes (mediastinal, inguinal, popliteal), muscle
(quadriceps femoris) and the primary tumor. Slides of all
samples were stained with hematoxylin and eosin (HE).
Additionally immunohistology was performed with the aim
to identify adenocarcinoma cells within primary tumor and
to identify possible metastasis in lymph nodes. Serial sec-
tions were deparaffinized, heat-mediated antigen retrieval
was conducted (95 °C, 20 min) and sections were incubated
in room temperature overnight with following primary
antibodies: Pan-Cytokeratin, PSA and Galactin-3 (Table 3).
Secondary anti-mouse IgG was applied in (1:200 dilution)
for 30 min followed by the Amino-9-ethyl-carbazole (AEC)
substrate kit as a chromogen. Finally the sections were
counter-stained with Gill’s hematoxylin for 3 min and
cover-slipped with an aqueous mounting media.
All slides were examined and semiquantitatively evalu-
ated (Table 4).
Statistic
Statistical analysis was performed with SPSS. Descriptive
analysis (median, min, max) was performed for continu-
ous variables. Taking into account that the number of
examined rats was limited, the population distribution
was not assumed to be normal. Consequently, nonpara-
metric rank sum tests (Mann-Whitney U-test) were used to
assess differences between groups. For all values p < 0.05
was considered to be significant.
Additional files
Additional file 1: Score sheet for animal health. (PDF 51 kb)
Additional file 2: Pathogen cell tests. (PDF 41 kb)
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